-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SPALuWD3RYjQqSMmKP9/T0k2ROy6/sl5W0Dv098S1G9a/dD0XITU4zk9/wD7qhyA HsW1BGTGE435Eveph+HWbQ== 0001209191-10-052018.txt : 20101028 0001209191-10-052018.hdr.sgml : 20101028 20101028180402 ACCESSION NUMBER: 0001209191-10-052018 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101028 FILED AS OF DATE: 20101028 DATE AS OF CHANGE: 20101028 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hove Anders D CENTRAL INDEX KEY: 0001365618 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33054 FILM NUMBER: 101149260 MAIL ADDRESS: STREET 1: 30 ROCKEFELLER PLAZA, SUITE 5508 CITY: NEW YORK STATE: NY ZIP: 10112 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Trubion Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001298521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2401 4TH AVENUE STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2068380500 MAIL ADDRESS: STREET 1: 2401 4TH AVENUE STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2010-10-28 1 0001298521 Trubion Pharmaceuticals, Inc TRBN 0001365618 Hove Anders D C/O VENROCK ASSOCIATES 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036 1 0 0 0 Common Stock 2010-10-28 4 D 0 308367 D 0 I By Venrock Partners, L.P. Common Stock 2010-10-28 4 D 0 1512111 D 0 I By Venrock Associates IV, L.P. Common Stock 2010-10-28 4 D 0 37154 D 0 I By Venrock Entrepreneurs Fund IV, L.P. Stock Option (right to purchase) 13.78 2010-10-28 4 D 0 12500 0.00 D 2016-10-24 Common Stock 12500 0 D Stock Option (right to purchase) 19.08 2010-10-28 4 D 0 5000 0.00 D 2017-05-25 Common Stock 5000 0 D Stock Option (right to purchase) 6.63 2010-10-28 4 D 0 5000 0.00 D 2018-05-28 Common Stock 5000 0 D Stock Option (right to purchase) 2.28 2010-10-28 4 D 0 5000 0.00 D 2019-05-27 Common Stock 5000 0 D Stock Option (right to purchase) 3.45 2010-10-28 4 D 0 5000 0.00 D 2020-05-26 Common Stock 5000 0 D Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $420,920.96 cash, (b) 50,603 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 308,367 contingent value rights, which represent the right to receive possible additional cash payments. Venrock Partners, L.P. is a limited partership, the general partner of which is Venrock Partners Management, LLC. The reporting person is a member of Venrock Partners Managment, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $2,064,031.52 cash, (b) 248,137 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 1,512,111 contingent value rights, which represent the right to receive possible additional cash payments. Venrock Associates IV, L.P. is a limited partership, the general partner of which is Venrock Partners Management, LLC. The reporting person is a member of Venrock Partners Managment, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $50,715.21 cash, (b) 6,097 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 37,154 contingent value rights, which represent the right to receive possible additional cash payments. Venrock Entrepreneurs Fund IV, L.P. is a limited partership, the general partner of which is VEF Management IV, LLC. The reporting person is a member of VEF Management IV, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. This option, which was 100% vested on October 23, 2009, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received. This option, which was 100% vested on May 27, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received. This option, which was 100% vested on May 15, 2009, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received. This option, which was 100% vested on May 26, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $11,350, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments. This option, which was to be 100% vested on May 25, 2011, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $5,500, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments. /s/ Kathleen Deeley as attorney-in-fact for Anders D. Hove 2010-10-28 -----END PRIVACY-ENHANCED MESSAGE-----